Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | CPN1 | P15169 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24838517 | 1.00 | DPP4 (0.44) | DPP4CPN1CPB2KCNH2SLC6A2 | |
| SCHEMBL9210144 | 0.86 | — | — | |
| SCHEMBL4500790 | 0.86 | — | — | |
| SCHEMBL19251155 | 0.86 | — | — | |
| SCHEMBL13738433 | 0.86 | — | — | |
| SCHEMBL2266330 | 0.86 | — | — | |
| Iodide SCHEMBL9406526 | 0.85 | KCNH2 (0.36) | DPP4KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22798913 | 0.82 | DPP4 (0.42) | DPP4CPN1CPB2SLC6A2SLC6A4 | |
| SCHEMBL5025923 | 0.82 | — | — | |
| SCHEMBL6082609 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768868-B | Pyridazinone thio derivative and preparation method and application thereof | 云南省药物研究所 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-116768868-A | Pyridazinone thio derivative and preparation method and application thereof | 云南省药物研究所 | 2023-09-19 | — | — | CN | disclosed |
| EP-3515916-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-114014845-B | Epoxy group-containing compound, liquid crystal aligning agent, and preparation method and application thereof | 波米科技有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| CN-114014845-A | Epoxy group-containing compound, liquid crystal aligning agent, and preparation method and application thereof | 波米科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8372851-B2 | Pyrazolo pyrimidines as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| EP-1948663-B1 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010036632-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| EP-1948663-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007048066-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| CN-1040436-C | Pharmaceuticals | SMITHKLINE BEECHAM PLC (GB) | 1998-10-28 | — | — | CN | disclosed |
| CN-1073173-A | Preparation method as the compound of 5-hydroxytryptamine receptor antagonist | SMITHKLINE BEECHAM PLC (GB) | 1993-06-16 | — | — | CN | disclosed |
| US-4220764-A | Preparation of tertiary heterocyclic amines | UOP INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4179469-A | Preparation of amines | UOP INC. (US) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | DPP4 3185/4885CPN1 3604/4885CPB2 3522/4885 |
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | CSNK1A1, CSNK2A1, CSNK2A2 | DPP4 1268/4885CPN1 420/4885CPB2 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.